SCHEMBL20118979

SCHEMBL20118979

COC(=O)c1ccc(C)cc1-c1cccnc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP46A1 Q9Y6A2 1/20 0.56
SLC2A1 P11166 1/20 0.54
NR4A2 P43354 3/20 0.54
CFTR P13569 1/20 0.54
CYP11B1 P15538 2/20 0.51
CYP11B2 P19099 2/20 0.51
CYP19A1 P11511 1/20 0.51
ALDH1A1 P00352 2/20 0.50
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA3 P34903 1/20 0.49
GABRA2 P47869 1/20 0.49
MAPK1 P28482 1/20 0.49
MKNK1 Q9BUB5 2/20 0.48
MKNK2 Q9HBH9 2/20 0.48
HDAC7 Q8WUI4 1/20 0.48
CYP2A6 P11509 1/20 0.48
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515912 0.84 CFTR (0.53) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL3515844 0.84 NR4A2 (0.57) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL20118977 0.84 NPC1 (0.53) ALDH1A1MKNK1MKNK2HDAC7CYP2A6
SCHEMBL3517564 0.83 CYP11B1 (0.55) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL20178609 0.83 CFTR (0.52) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL6776148 0.83 HDAC7 (0.67) CYP46A1NR4A2ALDH1A1GABRA1GABRG2
SCHEMBL20173748 0.82 NR4A2 (0.51) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL30118927 0.82 KMT2A (0.61) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL13435236 0.82 KMT2A (0.61) SLC2A1NR4A2CFTRCYP11B1CYP11B2
SCHEMBL29644805 0.82 KMT2A (0.61) SLC2A1NR4A2CFTRCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
WO-2018081285-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 CYP46A1 158/4885SLC2A1 845/4885NR4A2 585/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 CYP46A1 158/4885SLC2A1 845/4885NR4A2 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.